Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Minomic International Ltd.
DescriptionAntibody-drug conjugate that binds glypican 1 (GPC1)
Molecular Target Glypican 1 (GPC1)
Mechanism of ActionAntibody-drug conjugate
Therapeutic ModalityBiologic: Antibody-drug conjugate
Latest Stage of DevelopmentPreclinical
Standard IndicationProstate cancer
Indication DetailsTreat prostate cancer
Regulatory Designation
PartnerCatalent Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today